Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: modernatx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/26/2024 | $75.00 → $86.00 | Hold → Reduce | HSBC Securities |
1/2/2024 | $142.00 | Perform → Outperform | Oppenheimer |
11/29/2023 | $82.00 | Hold | Canaccord Genuity |
11/3/2023 | $89.00 → $69.00 | Reduce → Hold | HSBC Securities |
11/2/2023 | $125.00 → $60.00 | Hold → Sell | Deutsche Bank |
8/4/2023 | $145.00 → $125.00 | Outperform → Market Perform | TD Cowen |
8/3/2023 | $125.00 | Buy → Hold | Deutsche Bank |
7/24/2023 | $136.28 | Mkt Perform | William Blair |
7/14/2023 | $97.00 | Reduce | HSBC Securities |
6/26/2023 | $221.00 → $191.00 | Neutral → Buy | UBS |
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billionInitiated three new clinical studies evaluating Moderna's investigational individualized neoantigen therapy in combination with Merck's Keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinomaAdvanced three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials as announced at Vaccines Day investor eventCAMBRIDGE, MA / ACCESSWIRE / May 2, 2024 / Mod
CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its first quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancemen
Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) billion and GAAP diluted EPS of $(12.33); loss primarily driven by mostly non-cash charges of $3.7 billion related to resizing and a tax valuation allowanceReaffirms 2024 expected product sales of approximately $4 billionExpects regulatory approvals for its investigational RSV vaccine for older adults beginning in first half of 2024, and anticipates additional key milestones from its late-stage pipeline this yearCAMBRIDGE, MA / ACCESSWIRE / February 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial result
CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine.
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billionSpikevax U.S. market share to date increased to 45% from 36% in 2022Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025Company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven by mostly non-cash charges of $3.1 billion related to resizing and a tax valuation allowanceCompany's late-stage pipeline has six Phase 3 programsCompany expects to break even in 2026 through product launches and disciplined investmentCAMBRIDGE, MA / ACCESSWIRE / November 2,
CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023 to report its third quarter 2023 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaIn over 10 years since its inception, Moderna has transformed from a research-stage
Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62Company expecting 2023 COVID-19 vaccine sales of $6 billion to $8 billion, dependent on U.S. vaccination ratesCompany submitted its investigational RSV vaccine to several regulators globally ahead of potential 2024 launchWith its partner Merck, the Company began Phase 3 trial of mRNA-4157, its individualized neoantigen therapy (INT), in combination with Keytruda®, for high-risk melanomaCAMBRIDGE, MA / ACCESSWIRE / August 3, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business
CAMBRIDGE, MA / ACCESSWIRE / July 13, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023 to report its second quarter 2023 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaIn
First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19Company in negotiations for new orders for fall of 2023 in U.S., Japan, and EU, in addition to reiterating 2023 minimum sales expectations of approximately $5.0 billion from previously announced COVID-19 vaccine Advanced Purchase AgreementsCompany preparing for potential 2024 commercial launch of its investigational RSV vaccine for older adultsCompany to begin Phase 3 trial this year of mRNA-4157, Moderna's individualized neoantigen therapy (INT) in combination with Keytruda®, for melanomaCompany preparing for six major vaccine launches from respiratory franchise (COVID-19, RSV, Flu, and
Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12Company reiterating approximately $5 billion in COVID-19 sales contracted for delivery in 2023 and expecting additional sales from key marketsCompany will file for regulatory approval for mRNA-1345, Moderna's investigational RSV vaccine for older adults, in the first half of 2023. mRNA-1345 was recently granted FDA Breakthrough Therapy DesignationmRNA-1010 Phase 3 flu vaccine interim efficacy analysis expected to be reviewed by an independent DSMB before the end of the first quartermR
Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 9 uncommon options trades for Moderna. This isn't normal. The overall sentiment of these big-money traders is split between 44% bullish and 44%, bearish. Out of all of the special opt
Signs are emerging that the market boom surrounding artificial intelligence (AI) might be taking on the characteristics of a bubble. This warning comes from Wall Street veteran investor Ed Yardeni, President of Yardeni Research, Inc., in a note to clients on July 4. “While we love the productivity-enhancing possibilities that AI offers, the AI phenomenon has many of the hallmarks of an inflating bubble,” Yardeni cautioned. He noted that there are “big bucks chasing the AI dream,” with substantial funds directed toward companies leveraging AI technology. ‘Too Much Capital Can End Even The Best Of Parties’ This year alone, Yardeni Research highlighted several advancements AI ca
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 37.68% on an annualized basis producing an average annual return of 50.84%. Currently, Moderna has a market capitalization of $44.44 billion. Buying $1000 In MRNA: If an investor had bought $1000 of MRNA stock 5 years ago, it would be worth $8,114.07 today based on a price of $115.95 for MRNA at the time of writing. Moderna's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and revi
Moderna, Inc. (NASDAQ:MRNA) shares are trending on Wednesday. The company received a $176 million award from the Rapid Response Partnership Vehicle to boost Influenza vaccine development. What To Know: On Tuesday, the company announced this award which will aid in the development of an mRNA-based vaccine against the H5 influenza virus. “mRNA vaccine technology offers advantages in efficacy, speed of development, and production scalability and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic,” said Stéphane Bancel, Chief Executive Officer of Moderna. Last year the company started a Phase 1/2 study of possible vaccine candidates ag
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens the door to a more personalized and effective treatment as messenger RNA instructs the patient’s cells how to combat diseases like cancer. Moderna Inc (NASDAQ:MRNA) and Merck & Co (NYSE:MRK) joined forces to advance cancer treatment with an experimental mRNA vaccine, used in combination with Merck’s blockbuster immunotherapy drug Keytruda. With promising mid-stage trial results in the battle against melanoma, the duo is also conducting a late-stage study to validate their findings and expand t
Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA) are set for more legal battles over their rival COVID-19 vaccines after London’s High Court delivered a mixed ruling on two of Moderna’s patents. This decision is likely to trigger a series of appeals in the ongoing London litigation. Pfizer and its German partner BioNTech SE (NASDAQ:BNTX) initiated the lawsuit against Moderna in London in September 2022, seeking to revoke two of Moderna’s patents. In response, Moderna accused Pfizer and BioNTech of infringing on its patents. These lawsuits are part of a global legal struggle over messenger RNA (mRNA) technology. Read Next: European Patent Office Sides with Moderna In COVID-19
- Reuters
- Reuters
In response to the growing threat of the H5N1 bird flu virus, the U.S. government has awarded a $176 million contract to Moderna Inc. (NASDAQ:MRNA) to accelerate the development of its bird flu vaccine. What Happened: Moderna revealed on Tuesday that it had received significant funding from the U.S. Biomedical Advanced Research and Development Authority, Reuters reported. The funds will be utilized to finalize the late-stage development and testing of a pre-pandemic mRNA-based vaccine against H5N1 avian influenza. The contract also includes additional measures to prepare and expedite a response to future public health threats. This action follows the first reported outbreak of the H5N1
HSBC Securities downgraded Moderna from Hold to Reduce and set a new price target of $86.00 from $75.00 previously
Oppenheimer upgraded Moderna from Perform to Outperform and set a new price target of $142.00
Canaccord Genuity initiated coverage of Moderna with a rating of Hold and set a new price target of $82.00
HSBC Securities upgraded Moderna from Reduce to Hold and set a new price target of $69.00 from $89.00 previously
Deutsche Bank downgraded Moderna from Hold to Sell and set a new price target of $60.00 from $125.00 previously
TD Cowen downgraded Moderna from Outperform to Market Perform and set a new price target of $125.00 from $145.00 previously
Deutsche Bank downgraded Moderna from Buy to Hold and set a new price target of $125.00
William Blair initiated coverage of Moderna with a rating of Mkt Perform and set a new price target of $136.28
HSBC Securities initiated coverage of Moderna with a rating of Reduce and set a new price target of $97.00
UBS upgraded Moderna from Neutral to Buy and set a new price target of $191.00 from $221.00 previously
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).The project award will support late-stage development for an mRNA-based vaccine to enable the licensure of a pre-pandemic vaccine against H5 influenza virus. This subtype of influenza virus causes a highly infectio
CAMBRIDGE, MA / ACCESSWIRE / June 28, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization in the European Union for mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. Following the CHMP's positive opinion, the European Commission will adopt a decision on the authorization of mRESVIA."The positive opinion from the EMA CHMP for mRESVIA highlights the innovation and adaptability of our mRNA plat
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and olderHigher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older CAMBRIDGE, MA / ACCESSWIRE / June 13, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine, has met its primary efficacy endpoint, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax. The Company also announced that higher efficacy was observed in adults 18 years of age and older compare
First exploration agreement initiated under strategic partnership between Flagship and Pfizer to accelerate the development of innovative medicines Collaboration leverages ProFound's proprietary ProFoundry™ Platform to identify potential novel protein therapeutics from the expanded human proteome ProFound and Pioneering Medicines, Flagship's in-house drug development unit will jointly conduct exploration activities CAMBRIDGE, Mass., June 12, 2024 /PRNewswire/ -- Flagship Pioneering and ProFound™ Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a multitude of diseases, today announced a collaboration to conduct foundational researc
mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and COVID-19, has met its primary endpoints, eliciting a higher immune response than the licensed comparator vaccines used in the trial."Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer
Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1."For four years, Moderna has consistently delivered vaccines that offer protection against COVID-19, and work is well underway to provide a vaccine targeting JN.1," said Stéphane Bancel, CEO of Moderna. "Staying up to date with your COVID-19 vaccine remains one of the best ways to protect yourself
Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address unmet medical needs for rare diseases CAMBRIDGE, MA / ACCESSWIRE / June 6, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. mRNA-3705 is an investigational therapeutic for methylmalonic acidemia (MMA) due to methylmalonic-CoA mutase (MUT) deficiency."We are excited about this opportunity and proud that our investigational mRNA therapeutic for MMA was selected by the U.S. FDA for the
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patientsThe 2.5-year recurrence-free survival rate of mRNA-4157 (V940) in combination with KEYTRUDA was 74.8% as compared to 55.6% for KEYTRUDA alone, with the benefit observed across exploratory subgroupsThe companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer, in addition to Phase 2 studies in patients with renal cell carcinoma and urothelial carcinoma and a Phase 2/3 study for cutaneous squa
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna."The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform," said Stéphane Bancel, Chi
Moderna to host an investor event via webcast on Monday, June 3 at 6:15 PM CDTCAMBRIDGE, MA / ACCESSWIRE / May 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 - June 4 in Chicago, IL. mRNA-4157 (V940) is being jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.The three abstract titles are:Abstract #TPS9616: INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatme
For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm
O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar
Banks was Most Recently the President and CEO of Tyson Foods and has been a Board Member of Indigo since July 2022 Company Closes Financing Round at Nearly $270 Million Indigo Also Appoints Nader Bekhouche and Noubar Afeyan to Board of Directors CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Be
Memorandum of Understanding with UK Government Outlines Areas of Cooperation CAMBRIDGE, Mass. and LONDON, Nov. 27, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation. The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.
CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced that John Lepore, M.D., will join Flagship Pioneering as CEO-Partner, and ProFound as Chief Executive Officer, effective October 16, 2023. Dr. Lepore joins ProFound after 17 years at GSK where he had extensive experience leading large international R&D organizations across diverse t
ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced the appointment of Klaus Urbahns, Ph.D., as Chief Scientific Officer. Urbahns will lead the Company's platform and drug discovery and development efforts to advance first-in-class therapeutics leveraging the company's ProFoundry™ Platform. Urbahns brings three decades of robust drug discovery and development experience to ProFound, with a successful track record in discovering and advancing first-in-human medicines from the lab to the clinic. He joins ProFound after 13 years at Merck KGaA, where he m
CAMBRIDGE, Mass., Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer. In this role, she will be responsible for driving and supporting business development across the Flagship ecosystem, leading the effort to forge strong partnerships between Flagship companies and the biopharma industry. She will also work closely with the Pioneering Medicines unit of Flagship as we continue to invest in and grow our corporate alliance strategy. "Partner
CAMBRIDGE, Mass., Aug. 29, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as Growth Partner. In this role, he will help scale and grow several Flagship-founded companies, working together with leaders at Flagship and its ecosystem of companies on organizational development, long-term strategy, financing, and business development. Khougazian joins Flagship from Sanofi where he spent over two decades most recently leading Sanofi's engagement in global emerging markets inc
CAMBRIDGE, Mass., Aug. 14, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act specifically at the site of disease and nowhere else, today announced that Jason Gardner, Ph.D., has joined Flagship Pioneering as CEO-Partner, and Ampersand as Chief Executive Officer and member of its Board of Directors. Gardner brings more than two decades of leadership experience across pharmaceutical and biotechnology companies, with deep expertise in drug discovery and development, and a succ
Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar
- Michael Severino, M.D. and Andreas Fibig bring decades of drug development and commercialization leadership experience to Montai Montai Health, a company unlocking the power of nature with digital technologies to treat and preempt chronic disease, today announced the appointment of Michael Severino, M.D., and Andreas Fibig to the Company's Board of Directors. Dr. Severino and Mr. Fibig bring decades of drug development and commercialization leadership experience to Montai, where their expertise and support will be critical as the company advances its artificial intelligence (AI) platform to enable the predictable discovery of breakthrough small molecules for chronic disease. "I'm thri